Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 3;10(6):ofad240.
doi: 10.1093/ofid/ofad240. eCollection 2023 Jun.

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

Takeshi Arashiro  1   2   3   4 , Yuzo Arima  1 , Jin Kuramochi  5   6 , Hirokazu Muraoka  7 , Akihiro Sato  8 , Kumi Chubachi  9 , Atsushi Yanai  10 , Hiroko Arioka  10 , Yuki Uehara  11   12 , Genei Ihara  13 , Yasuyuki Kato  14 , Naoki Yanagisawa  15 , Akihiro Ueda  16 , Hideaki Kato  17 , Hideaki Oka  18 , Yusuke Nishida  18 , Yuki Nidaira  5 , Takahiro Asami  19 , Torahiko Jinta  20 , Akira Nakamura  21 , Kunihiro Oba  22 , Daisuke Taniyama  23 , Kei Yamamoto  18 , Katsushi Tanaka  17 , Kankuro Ueshima  24 , Tetsuji Fuwa  24 , Ashley Stucky  1 , Tadaki Suzuki  2 , Chris Smith  3   4 , Martin Hibberd  3 , Koya Ariyoshi  4 , Motoi Suzuki  1
Affiliations

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

Takeshi Arashiro et al. Open Forum Infect Dis. .

Abstract

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 variants; test-negative design; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. TA is an unpaid consultant for the World Health Organization. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health . VIEW-hub: COVID-19 data, vaccine effectiveness studies. Available at: https://view-hub.org/covid-19/effectiveness-studies. Accessed 14 April 2023.
    1. Ministry of Health, Labour and Welfare/National Institute of Infectious Diseases, Japan . [Seroprevalence among blood donors]. Available at: https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/11729-covid19-82.html. Accessed 14 April 2023.
    1. Arashiro T, Arai S, Kinoshita R, et al. . National seroepidemiological study of COVID-19 after the initial rollout of vaccines: before and at the peak of the omicron-dominant period in Japan. Influenza Other Respir Viruses 2023; 17:e13094. - PMC - PubMed
    1. Arashiro T, Arima Y, Muraoka H, et al. . COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and omicron-dominant periods in Japan: a multi-center prospective case-control study (factors associated with SARS-CoV-2 infection and the effectiveness of COVID-19 vaccines study). Clin Infect Dis 2023; 76:e108–15. - PMC - PubMed
    1. Ministry of Health, Labour and Welfare, Japan . [Estimated subvariant prevalence via SARS-CoV-2 genomic surveillance using specimen from commercial company]. Available at: https://www.mhlw.go.jp/content/10900000/001039363.pdf. Accessed 14 April 2023.